Prevention of nafld development in rats with obesity via the improvement of pro/antioxidant state by cerium dioxide nanoparticles

Clujul Medical

Volumn 89, Issue 2, 2016, Pages 229-235

  Kobyliak, Nazarii ^a   Abenavoli, Ludovico ^b   Falalyeyeva, Tetyana ^c   Virchenko, Oleksandr ^c   Natalia, Belemets ^c   Beregova, Tetyana ^c   Bodnar, Petro ^a   Spivak, Mykola ^d  

^a BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

^d INSTITUTE OF HYDROBIOLOGY   (Ukraine)

Author keywords

Lipid peroxidation; Nanoparticles; Non alcoholic fatty liver disease; Reactive oxygen species; Wistar rats

Indexed keywords

EID: 84964937676     PISSN: 12222119     EISSN: 20668872     Source Type: Journal    
DOI: 10.15386/cjmed-632     Document Type: Article

References (34)

1. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197-1209.
2. Borrell LN, Samuel L. Body mass index categories and mortality risk in US adults: the effect of overweight and obesity on advancing death. Am J Public Health. 2014;104:512-519.
3. Ma J, Flanders WD, Ward EM, Jemal A. Body mass index in young adulthood and premature death: analyses of the US National Health Interview Survey linked mortality files. Am J Epidemiol. 2011;174:934-944.
4. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.
5. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9:126-133.
6. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871.
7. Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol. 2014;20:16831-16840.
8. Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, et al. Effects of Mediterranean diet supplemented with silybinvitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:519-527.
9. Minarchick VC, Stapleton PA, Sabolsky EM, Nurkiewicz TR. Cerium Dioxide Nanoparticle Exposure Improves Microvascular Dysfunction and Reduces Oxidative Stress in Spontaneously Hypertensive Rats. Front Physiol. 2015;6:339.
10. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:14205-14218.
11. Yefimenko OY, Savchenko YO, Falalyeyeva TM, Beregova TV, Zholobak NM, Spivak MY, et al. Nanocrystalline cerium dioxide efficacy for gastrointestinal motility: potential for prokinetic treatment and prevention in elderly. EPMA J. 2015;6(1):6.
12. Kobyliak NM, Falalyeyeva TM, Kuryk OG, Beregova TV, Bodnar PM, Zholobak NM, et al. Antioxidative effects of cerium dioxide nanoparticles ameliorate age-related male infertility: optimistic results in rats and the review of clinical clues for integrative concept of men health and fertility. EPMA J. 2015;6(1):12.
13. Savcheniuk OA, Virchenko OV, Falalyeyeva TM, Beregova TV, Babenko LP, Lazarenko LM, et al. The efficacy of probiotics for monosodium glutamate-induced obesity: dietology concerns and opportunities for prevention. EPMA J. 2014;5:2.
14. Savcheniuk O, Kobyliak N, Kondro M, Virchenko O, Falalyeyeva T, Beregova T. Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity. BMC Complement Altern Med. 2014;14:247.
15. Kondro M, Mykhalchyshyn G, Bodnar P, Kobyliak N, Falalyeyeva T. Metabolic profile and morpho-functional state of the liver in rats with glutamate-induced obesity. Curr Issues Pharm Med Sci. 2013;26:379-381.
16. Kobyliak N, Abenavoli L. The role of liver biopsy to assess non-alcoholic fatty liver disease. Rev Recent Clin Trials. 2014;9:159-169.
17. Gavrilov VB, Gavrilova AR, Khmara NF. Measurement of diene conjugates in blood plasma using the UV absorption of heptane and isopropanol extracts. Lab Delo. 1988;(2):60-64.
18. Kolesova OE, Markin AA, Fedorova TN. Lipid peroxidation and methods of determining its products in biological media. Lab Delo. 1984;(9):540-546.
19. Chevari S, Chaba I, Sekeĭ I. Role of superoxide dismutase in cellular oxidative processes and method of its determination in biological materials. Lab Delo. 1985;(11):678-681.
20. Koroliuk MA, Ivanova LI, Maĭorova IG, Tokarev VE. A method of determining catalase activity. Lab Delo. 1988;(1):16-19.
21. Shrivastava A, Chaturvedi U, Singh SV, Saxena JK, Bhatia G. Lipid lowering and antioxidant effect of miglitol in triton treated hyperlipidemic and high fat diet induced obese rats. Lipids. 2013;48:597-607.
22. Shcherbakov AB, Zholobak NM, Ivanov K, Tretyakov Yu D, Spivak NY. Nanomaterials based on the nanocrystalline ceria: properties and use perspectives in biology and medicine. Biotechnologia Acta. 2011;4:9-28.
23. Shcherbakov AB, Ivanov VK, Zholobak NM, Ivanova OS, Krysanov E.I., Baranchikov AE, et al. Nanocrystaline ceria based materials--perspectives for biomedical application. Biofizika. 2011;56:995-1015.
24. Nolan M, Parker SC, Watson GW. Reduction of NO2 on ceria surfaces. J Phys Chem B. 2006;110:2256-2262.
25. Hochella MF Jr, Lower SK, Maurice PA, Penn RL, Sahai N, Sparks DL, et al. Nanominerals, mineral nanoparticles, and earth systems. Science. 2008;319:1631-1635.
26. Naganuma T, Traversa E. Stability of the Ce3+ valence state in cerium oxide nanoparticle layers. Nanoscale. 2012;4:4950-4953.
27. Deshpande S, Patil S, Kuchibhatla SVNT, Seal S. Size Dependency Variation in Lattice Parameter and Valency States in Nanocrystalline Cerium Oxide. Appl Phys Lett. 2005;87:133113-133116.
28. Celardo I, Traversa E, Ghibelli L. Cerium oxide nanoparticles: a promise for applications in therapy. J Exp Ther Oncol. 2011;9:47-51.
29. Das S, Dowding JM, Klump KE, McGinnis JF, Self W, Seal S. Cerium oxide nanoparticles: applications and prospects in nanomedicine. Nanomedicine (Lond). 2013;8:1483-1508.
30. Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM. Anti-inflammatory properties of cerium oxide nanoparticles. Small. 2009;5:2848-2856.
31. Hirst SM, Karakoti A, Singh S, Self W, Tyler R, Seal S, et al. Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ Toxicol. 2013;28:107-118.
32. Tseng MT, Lu X, Duan X, Hardas SS, Sultana R, Wu P, et al. Alteration of hepatic structure and oxidative stress induced by intravenous nanoceria. Toxicol Appl Pharmacol. 2012;260:173-182.
33. Rocca A, Moscato S, Ronca F, Nitti S, Mattoli V, Giorgi M, et al. Pilot in vivo investigation of cerium oxide nanoparticles as a novel anti-obesity pharmaceutical formulation. Nanomedicine. 2015;11:1725-1734.
34. Pourkhalili N, Hosseini A, Nili-Ahmadabadi A, Hassani S, Pakzad M, Baeeri M, et al. Biochemical and cellular evidence of the benefit of a combination of cerium oxide nanoparticles and selenium to diabetic rats. World J Diabetes. 2011;2:204-210.